PBS delisting triggers govt intervention on diabetes drug
Affected patients are advised to see their doctor for a new script before 1 April.
The Federal Government says fast-acting insulin products Fiasp and Fiasp FlexTouch will be subsidised for patients with type 1 diabetes for an extra six months as part of an emergency stopgap measure.
Last week, Minister for Health and Aged Care Mark Butler issued a Supply Only arrangement after the sponsor Novo Nordisk announced it would remove the medication from the PBS on 1 April.
